Hypomethylating agent based combinations in higher risk myelodysplastic syndrome

References

• Steensma DP. Myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2015;90(7):969–983.
   PubMed Web of Science ®Google Scholar
• de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000;110(3):620–630.
   PubMed Web of Science ®Google Scholar
• Gurion R, Vidal L, Gafter-Gvili A, et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome–a systematic review and meta-analysis. Haematologica. 2010;95(2):303–310.
   PubMed Web of Science ®Google Scholar
• Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010;24(2):287–294.
   PubMed Web of Science ®Google Scholar
• Sherman AE, Motyckova G, Fega KR, et al. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res. 2013;37(9):998–1003.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III Randomized Study. Cancer. 2006;106(8):1794–1803.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. JCO. 2002;20(10):2429–2440.
   PubMed Web of Science ®Google Scholar
• Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res. 2005;11(10):3604–3608.
   PubMed Web of Science ®Google Scholar
• Mozessohn L, Cheung MC, Fallahpour S, et al. Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada. Br J Haematol. 2018;181(6):803–815.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Stahl M, DeVeaux M, et al. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood Cancer J. 2018;8(6):55.
   PubMed Web of Science ®Google Scholar
• Derissen EJ, Beijnen JH, Schellens JH. Concise drug review: azacitidine and decitabine. Oncologist. 2013;18(5):619–624.
   PubMed Web of Science ®Google Scholar
• Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for research and treatment of cancer leukemia group and the German MDS study group. JCO. 2011;29(15):1987–1996.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Davidoff AJ, Long JB, et al. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016;175(5):829–840.
   PubMed Web of Science ®Google Scholar
• Lee Y-G, Kim I, Yoon S-S, et al. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. Br J Haematol. 2013;161(3):339–347.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA Approves Venetoclax in Combination for AML in Adults. 2018. Available from: https://www.fda.gov/drugs/fda-approves-venetoclax-combination-aml-adults
   Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765–3776.
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–1465.
   PubMed Web of Science ®Google Scholar
• Santini V, Almeida A, Giagounidis A, et al. Randomized phase III Study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. JCO. 2016;34(25):2988–2996.
   PubMed Web of Science ®Google Scholar
• Giagounidis AAN, Germing U, Haase S, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia. 2004;18(1):113–119.
   PubMed Web of Science ®Google Scholar
• Mollgard L, Saft L, Treppendahl MB, et al. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica. 2011;96(7):963–971.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Gundacker H, Lancet J, et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood. 2011;118(3):523–528.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Germing U. Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia—a wise liaison? Leukemia. 2013;27:1813.
   PubMed Web of Science ®Google Scholar
• Ades L, Récher C, Lejeune J, et al. A phase I-II study of the efficacy and safety of lenalidomide (LEN) combined to azacitidine (AZA) in higher risk MDS and AML with Del 5q - a study by the Groupe Francophone Des Myelodysplasies (GFM). Blood. 2015;126(23):2892.
   Web of Science ®Google Scholar
• Sekeres MA, Othus M, List AF, et al. Randomized Phase II Study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. JCO. 2017;35(24):2745–2753.
   PubMed Web of Science ®Google Scholar
• Kenealy M, Hertzberg M, Benson W, et al. Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. Haematologica. 2019;104(4):700–709.
   PubMed Web of Science ®Google Scholar
• Kenealy M, Benson W, Stevenson W, et al. 13 the addition of lenalidomide to azacitidine achieves higher responses but no improvement in twelve month clinical benefit or PFS; main analysis Australian ALLG MDS4 trial. Leukemia Res. 2015;39:S5.
   Web of Science ®Google Scholar
• Ades L, Guerci A, Laribi K, et al. A Randomized PHAse II Study of azacitidine (AZA) Alone or with lenalidomide (LEN), valproic acid (VPA) or idarubicin (IDA) in higher-risk MDS: Gfm's 'pick a Winner' Trial. Blood. 2018;132(Supplement 1):467.
   PubMedGoogle Scholar
• Rasmussen B, Nilsson L, Jädersten M, et al. A Randomized Phase II study of standard dose azacitidine alone or in combination with lenalidomide in high risk MDS with a KAryotype including DEL(5Q). EHA Library. 2018;214575:S1556.
   Google Scholar
• Ades L, Boehrer S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood. 2009;113(17):3947–3952.
   PubMed Web of Science ®Google Scholar
• Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13(9):673.
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6(1):38–51.
   PubMed Web of Science ®Google Scholar
• Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6(4):a018713.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Santos FPS, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia. 2011;25(2):226.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111(3):1060–1066.
   PubMed Web of Science ®Google Scholar
• Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007;109(7):2781–2790.
   PubMed Web of Science ®Google Scholar
• Hackanson B, Rimmele L, Benkißer M, et al. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. Leuk Res. 2012;36(8):1055–1062.
   PubMed Web of Science ®Google Scholar
• Stahl M, Gore SD, Vey N, et al. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs. 2016;25(3):307–317.
   PubMed Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myöhänen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21(1):103.
   PubMed Web of Science ®Google Scholar
• Craddock CF, Houlton AE, Quek LS, et al. Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature. Clin Cancer Res. 2017;23(21):6430–6440.
   PubMed Web of Science ®Google Scholar
• Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. JCO. 2014;32(12):1242–1248.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Montalban-Bravo G, Berdeja JG, et al. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer. 2017;123(6):994–1002.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Atallah E, Khaled SK, et al. Final results from a phase 2 study of pracinostat in combination with azacitidine in elderly patients with acute myeloid leukemia (AML). Blood. 2015;126(23):453.
   Web of Science ®Google Scholar
• Keng MK, Khaled SK, Cooper B, et al. Planned interim analysis of a phase 2 study evaluating the combination of pracinostat, a histone deacetylase inhibitor (HDACi), and azacitidine in patients with high/very high-risk myelodysplastic syndrome (MDS). Blood. 2018;132(Suppl 1):4362.
   Google Scholar
• Stahl M, Zeidan AM. Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel? Cancer. 2017;123(6):911–914.
   PubMed Web of Science ®Google Scholar
• Fleming RA, Capizzi RL, Rosner GL, et al. Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. Cancer Chemother Pharmacol. 1995;36(5):425–430.
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Capparelli E, Lancet JE, et al. Enhanced cytarabine and daunorubicin population pharmacokinetics when administered as CPX-351: a novel liposomal formulation not requiring dose reduction for mild renal or hepatic dysfunction. Blood. 2016;128(22):3955.
   Web of Science ®Google Scholar
• Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058–1066.
   PubMed Web of Science ®Google Scholar
• Clark O, Yen K, Mellinghoff IK. Molecular pathways: isocitrate dehydrogenase mutations in cancer. Clin Cancer Res. 2016;22(8):1837.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Daver NG, Montalban-Bravo G, et al. A Phase II study evaluating the combination of nivolumab (Nivo) or ipilimumab (Ipi) with azacitidine in Pts with previously treated or untreated myelodysplastic syndromes (MDS). Blood. 2016;128(22):344.
   Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Eng J Med. 2013;368(22):2059–2074.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Maharry K, Wu Y-Z, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. JCO. 2010;28(14):2348–2355.
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–744.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–731.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398.
   PubMed Web of Science ®Google Scholar
• Stein EM, Fathi AT, DiNardo CD, et al. Enasidenib (AG-221), a Potent oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, induces hematologic responses in patients with myelodysplastic syndromes (MDS). Blood. 2016;128(22):343.
   Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553–567.
   PubMed Web of Science ®Google Scholar
• Ball B, Zeidan A, Gore SD, et al. Hypomethylating agent combination strategies in myelodysplastic syndromes: Hopes and shortcomings. Leuk Lymphoma. 2017;58(5):1022–1036.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein AS, Fathi AT, et al. Mutant isocitrate dehydrogenase (mIDH) inhibitors, enasidenib or ivosidenib, in combination with azacitidine (AZA): preliminary results of a phase 1b/2 study in patients with newly diagnosed acute myeloid leukemia (AML). Blood. 2017;130(Suppl 1):639.
   Google Scholar
• Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532–1542.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64.
   PubMed Web of Science ®Google Scholar
• Seiler M, Yoshimi A, Darman R, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018;24(4):497.
   PubMed Web of Science ®Google Scholar
• Steensma D, Kilmek V, Yang J, et al. Phase I dose escalation clinical trial of H3B-8800, a splicing modulator, in patients with advanced myeloid malignancies. In: Steensma D, editor. The European Hematology Association (EHA). Amsterdam, The Netherlands: EHA Library; 2019. p. 266651.
   Google Scholar
• Assi R, Kantarjian HM, Garcia-Manero G, et al. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018;93(2):277–285.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bykov VJN, Wiman KG, et al. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death Dis. 2018;9(5):439.
   PubMedGoogle Scholar
• Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490–1496.
   PubMed Web of Science ®Google Scholar
• Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. JCO. 2001;19(13):3244–3254.
   PubMed Web of Science ®Google Scholar
• Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31(9):1855–1868.
   PubMed Web of Science ®Google Scholar
• Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986–996.
   PubMed Web of Science ®Google Scholar
• Balaian L, Ball ED. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia. 2006;20(12):2093.
   PubMed Web of Science ®Google Scholar
• Nand S, Godwin J, Smith S, et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma. 2008;49(11):2141–2147.
   PubMed Web of Science ®Google Scholar
• Daver N, Kantarjian H, Ravandi F, et al. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 2016;30(2):268–273.
   PubMed Web of Science ®Google Scholar
• Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777–1784.
   PubMed Web of Science ®Google Scholar
• Li LJ, Tao JL, Fu R, et al. Increased CD34 + CD38 -CD123 + cells in myelodysplastic syndrome displaying malignant features similar to those in AML. Int J Hematol. 2014;100(1):60–69.
   PubMed Web of Science ®Google Scholar
• Syed K, Pietsch C, Axel A, et al. Preclinical Evaluation of CSL362/JNJ-56022473 in Combination with Decitabine or Azacitidine in in Vitro Assays. Blood. 2015;126(23):1370.
   Web of Science ®Google Scholar
• Mani R, Goswami S, Gopalakrishnan B, et al. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34(+)CD123(+) cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors. Haematologica. 2018;103(8):1288–1297.
   PubMed Web of Science ®Google Scholar
• Chichili GR, Huang L, Li H, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. 2015;7(289):289ra82.
   PubMed Web of Science ®Google Scholar
• Vey N, Davidson-Moncada JK, Uy GL, et al. A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS. JCO. 2017;35(15_suppl):TPS7070–TPS7070.
   Google Scholar
• Shamas-Din A, Kale J, Leber B, et al. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb Perspect Biol. 2013;5(4):a008714.
   PubMed Web of Science ®Google Scholar
• Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol. 2007;35(11):1739–1746.
   PubMed Web of Science ®Google Scholar
• Jilg S, Reidel V, Müller-Thomas C, et al. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. 2016;30(1):112.
   PubMed Web of Science ®Google Scholar
• Campos L, Rouault JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81(11):3091–3096.
   PubMed Web of Science ®Google Scholar
• Montero J, Letai A. Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ. 2018;25(1):56.
   PubMed Web of Science ®Google Scholar
• Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12(3):329–341.
   PubMed Web of Science ®Google Scholar
• Glaser SP, Lee EF, Trounson E, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012;26(2):120–125.
   PubMed Web of Science ®Google Scholar
• Bose P, Grant S. Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML). Leukemia Res Rep. 2013;2(1):12–14.
   PubMedGoogle Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117.
   PubMed Web of Science ®Google Scholar
• Jilg S, Kauschinger J, Reidel V, et al. Combination of 5-azacytidine and ABT-199 has a synergistic apoptotic effect in high-risk MDS/sAML after HMA failure. Blood. 2016;128(22):4297.
   Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228.
   PubMed Web of Science ®Google Scholar
• FDA approves venetoclax in combination for AML in adults. 2018 [cited 2019 Nov 27]. Available from: https://www.fda.gov/drugs/fda-approves-venetoclax-combination-aml-adults.
   Google Scholar
• Fong CY, Wei AH, Frattini MG, et al. Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes. JCO. 2018;36(15_suppl):TPS7082–TPS7082.
   Web of Science ®Google Scholar
• Isidori A, Salvestrini V, Ciciarello M, et al. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. Expert Rev Hematol. 2014;7(6):807–818.
   PubMed Web of Science ®Google Scholar
• Alatrash G, Daver N, Mittendorf EA. Targeting immune checkpoints in hematologic malignancies. Pharmacol Rev. 2016;68(4):1014–1025.
   PubMed Web of Science ®Google Scholar
• Boddu P, Kantarjian H, Garcia-Manero G, et al. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma. 2018;59(4):790–802.
   PubMed Web of Science ®Google Scholar
• Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(10):3044–3051.
   PubMed Web of Science ®Google Scholar
• Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375(2):143–153.
   PubMed Web of Science ®Google Scholar
• Daver N, Boddu P, Garcia-Manero G, et al. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 2018;32(5):1094–1105.
   PubMed Web of Science ®Google Scholar
• Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28(6):1280–1288.
   PubMed Web of Science ®Google Scholar
• Daver N, Garcia-Manero G, Basu S, et al. Nivolumab (Nivo) with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML) or frontline elderly AML. Blood. 2017;130(Suppl 1):1345.
   Google Scholar
• Garcia-Manero G, Sasaki K, Montalban-Bravo G, et al. A phase II study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome. Blood. 132(Supplement 1):465.
   Google Scholar
• Gerds A, Scott BL, Greenberg P, et al. PD-L1 blockade with atezolizumab in higher-risk myelodysplastic syndrome: an initial safety and efficacy analysis. 2018;132(Supplement 1):466–466.
   Google Scholar
• Barclay AN, van den Berg TK. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2014;32(1):25–50.
   PubMedGoogle Scholar
• Jaiswal S, Jamieson CHM, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271–285.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang L, Zhao F, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PloS One. 2015;10(9):e0137345-e0137345.
   Web of Science ®Google Scholar
• Sallman DA, Donnellan WB, Asch AS, et al. The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1B results. J Clin Oncol. 2019;37(15_suppl):7009–7009.
   Google Scholar
• Navada SC, Garcia-Manero G, Atallah E, et al. Phase II study of oral rigosertib combined with azacitidine in patients with higher-risk myelodysplastic syndromes (MDS). In: Steensma D, editor. The European Hematology Association (EHA). Amsterdam, The Netherlands: EHA Library; 2019. p. 267422.
   Google Scholar
• Dickinson M, Cherif H, Fenaux P, et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018;132(25):2629–2638.
   PubMed Web of Science ®Google Scholar
• Swaminathan M, Borthakur G, Kadia TM, et al. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma. 2019;60(9):2207–2213.
   PubMed Web of Science ®Google Scholar
• Voso MT, Santini V, Fabiani E, et al. Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica. 2014;99(4):613–619.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147–1152.
   PubMed Web of Science ®Google Scholar
• Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28(1):78–87.
   PubMed Web of Science ®Google Scholar
• Nazha A, Sekeres MA, Bejar R, et al. Genomic biomarkers to predict resistance to hypomethylating agents in patients with myelodysplastic syndromes using artificial intelligence. JCO Precision Oncol. 2019;(3):1–11.
   Google Scholar
• Moujalled DM, Pomilio G, Ghiurau C, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia. 2019;33(4):905–917.
   PubMed Web of Science ®Google Scholar
• Almasri J, Alkhateeb HB, Damlaj M, et al. Comparative analysis of azacitidine and decitabine in myelodysplastic syndromes: a systematic review and network meta-analysis. Blood. 2015;126(23):1692.
   Web of Science ®Google Scholar
• Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. JCO. 2009;27(11):1850–1856.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109(1):52–57.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. JCO. 2009;27(23):3842–3848.
   PubMed Web of Science ®Google Scholar
• Prebet T, Sun Z, Ketterling R, et al. A 10 day schedule of azacitidine induces more complete cytogenetic remissions than the standard schedule in myelodysplasia and acute myeloid leukemia with myelodysplasia-related changes: results of the E1905 US leukemia intergroup study. Blood. 2010;116(21):4013.
   Web of Science ®Google Scholar
• Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375(21):2023–2036.
   PubMed Web of Science ®Google Scholar
• Savona MR, Kolibaba K, Conkling P, et al. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. Am J Hematol. 2018;93(10):1199–1206.
   PubMed Web of Science ®Google Scholar
• Otsuka A, Astex Pharmaceuticals. Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASCERTAIN study of the novel oral cedazuridine and decitabine fixed-dose combination (ASTX727) in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). 2019. [cited 2019 October 10]; Available from: https://astx.com/portfolio-item/astex-pharmaceuticals-and-otsuka-announce-results-of-the-phase-3-ascertain-study-of-oral-cedazuridine-and-decitabine-fixed-dose-combination-astx727-in-subjects-with-mds-and-cmml/.
   Google Scholar
• Garcia-Manero G, Roboz G, Walsh K, et al. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019;6(6):e317–e327.
   PubMed Web of Science ®Google Scholar
• Sébert M, Renneville A, Bally C, et al. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica. 2019;104(8):1565–1571.
   PubMed Web of Science ®Google Scholar